Skip to content

Drug-drug interaction study of repaglinide with regard to CYP2C8 and OATP1B1

Drug-drug interaction study of repaglinide with regard to CYP2C8 and OATP1B1 - Drug-drug interaction study of repaglinide

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000015430
Enrollment
24
Registered
2014-10-15
Start date
2014-10-07
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

healthy male and female

Interventions

Substrate cocktail, wash out, substrate cocktail with clopidogrel Substrate cocktail, wash out, substrate cocktail with rifampicin Substrate cocktail, wash out, substrate cocktail with trimethoprim

Sponsors

Clinical Pharmacokinetics, Graduate School of Pharmaceutical Sciences, Kyushu University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: The investigators must ensure that all subjects being considered meet the ollowing inclusion criteria: 1) Japanese healthy male or female who is capable to understand and sign the informed consent 2) 20-45 years of age 3) BMI 17.6-26.4 4) good health as determined by physical examination, vital signs and laboratory tests 5) not pregnant.

Exclusion criteria

Exclusion criteria: The investigators must ensure that all subjects being considered meet the ollowing exclusion criteria or conditions: 1) history of allergy to any drugs 2) medical attention within 2 months prior to participation 3) donation of 200 mL or more of blood within 4 weeks prior to participation, or donation of component blood within 2 weeks prior to participation 4) donation of 400 mL or more of blood within 12 weeks prior to participation 5) recent (past 4 months) participation in other clinical trial for investigational new chemical entity 6) history of drug abuse 7) alcohol abuse 8) lactose intolerant.

Design outcomes

Primary

MeasureTime frame
Pharmacokinetics of substrate cocktail (repaglinide, pitavastatin and pioglitazone)

Countries

Japan

Contacts

Public ContactTomohiro Oyama

LTA Sugioka Memorial Hospital

tomohiro-oyama@lta-med.com092-662-3608

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026